Committed to generating robust clinical data on its CoreValve System for transcatheter aortic valve implantation, Medtronic, unveiled for the first time the complete one-year data from the "real world" Medtronic CoreValve ADVANCE Study. The one-year findings from the rigorous study showed low rates of mortality and stroke, along with significant and sustained hemodynamic performance. Consistent with positive one-month clinical outcomes previously reported, the ADVANCE Study demonstrated a low all-cause mortality rate of 17.9%, a cardiovascular mortality rate of 11.7%, and a very low and stable overall stroke rate of 4.5% at one year. Patients followed to one year also experienced significant and sustained improvements in hemodynamics due to the implanted CoreValve. In addition, patients experienced dramatic symptomatic improvements: while at baseline only 20 percent of patients were classified as New York Heart Association class I or class II, clinical symptoms markedly improved with 85% of patients in NYHA class I or II at 30 days, and 87% of patients in NYHA class I or II at 12 months.